Search Result

Results for "

nAChR alpha7

" in MedChemExpress (MCE) Product Catalog:

By Targets:	nAChR (115) 5-HT Receptor (11) Akt (2) Amyloid-β (1) Antibiotic (1) AP-1 (1) Apoptosis (4) Autophagy (1) Bacterial (4) Calcium Channel (1) Cholinesterase (ChE) (6) Dengue Virus (1) Drug Metabolite (4) Endogenous Metabolite (9) Environmental Pollutants (1) Epigenetic Reader Domain (2) ERK (3) Flavivirus (1) HIV (1) HSV (1) Interleukin Related (6) Isotope-Labeled Compounds (12) JAK (3) Mitophagy (1) mTOR (1) NF-κB (3) NO Synthase (3) Nuclear Factor of activated T Cells (NFAT) (1) p38 MAPK (2) Parasite (3) Potassium Channel (3) Reactive Oxygen Species (ROS) (1) Reference Standards (10) SARS-CoV (2) STAT (2) TNF Receptor (4) β-catenin (4)
By Research Areas:	Cancer (13) Cardiovascular Disease (4) Infection (4) Inflammation/Immunology (24) Metabolic Disease (4) Neurological Disease (103)
Click Chemistry:	Alkynes (1)

125

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Targets Recommended: nAChR

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-10019

Varenicline 1 Publications Verification CP 526555	nAChR	Neurological Disease Inflammation/Immunology Cancer
Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-P1264

α-Bungarotoxin 5+ Cited Publications	nAChR	Neurological Disease
α-Bungarotoxin is a competitive antagonist at nicotinic acetylcholine receptors (nAChRs). α-Bungarotoxin, a selective α7 receptor blocker, blocks α7 currents with an IC₅₀ of 1.6 nM and has no effects on α3β4 currents at concentrations up to 3 μM .

HY-14564A

GTS-21 dihydrochloride 10+ Cited Publications DMXB-A; DMBX-anabaseine	nAChR 5-HT Receptor	Inflammation/Immunology
GTS-21 dihydrochloride is a selective alpha7 nicotinic acetylcholine receptor *(α7-nAChR)* agonist with anti inflammatory and cognition enhancing activities. GTS-21 dihydrochloride is also a *α4β2* (K_i=20 nM for humanα4β2) and 5-HT3A receptor (IC₅₀=3.1 μM) antagonist .

HY-N0175

Cytisinicline 1 Publications Verification Cytisine; Sophorine; Baptitoxine	nAChR	Metabolic Disease Cancer
Cytisinicline (Cytisine) is an alkaloid. Cytisinicline (Cytisine) is a partial agonist of α4β2 nAChRs , and partial to full agonist at β4 containing receptors and α7 receptors . Has been used medically to help with smoking cessation .

HY-12560A

PNU-282987 10+ Cited Publications	nAChR 5-HT Receptor	Neurological Disease
PNU-282987 is a potent α7 nicotinic acetylcholine receptor (nAChR) agonist with an EC₅₀ of 154 nM. PNU-282987 is also a functional antagonist of the 5-HT₃ receptor with an IC₅₀ of 4541 nM. PNU-282987 can be used for the research of central and peripheral nervous systems .

HY-B0567

Dequalinium Chloride	Potassium Channel nAChR Apoptosis Bacterial Parasite	Infection Cancer
Dequalinium chloride is an Apamin (HY-P0256)-sensitive potassium channel selective blocker. Dequalinium chloride is a cationic, lipophilic mitochondrial poison. Dequalinium chloride is also an antagonist pf α7 nAChR, and an anti-microbial antiseptic agent with a broad bactericidal and fungicidal activity .

HY-12152

PNU-120596 1 Publications Verification NSC 216666	nAChR	Neurological Disease Inflammation/Immunology
PNU-120596 (NSC 216666) is a potent and selective α7 nAChR positive allosteric modulator (PMA) that can cross the blood-brain barrier, with an EC₅₀ of 216 nM. PNU-120596 is inactive against α4β2, α3β4, and α9α10 nAChRs. PNU-120596 has the potential for psychiatric and neurological disorders research .

HY-172236

Soclenicant BNC210; IW-2143	nAChR	Neurological Disease
Soclenicant (BNC210) is an orally active α7 nAChR negative alteration modulator (NAM) with no apparent side effects. Soclenicant exhibits acute anxiolytic activity in rodent models of anxiety. Soclenicant inhibits rat and human α7 nAChR currents (in stably transfected cell lines) induced by acetylcholine, nicotine, choline, and the a7-specific agonist PNU-282987 (HY-12560A) with IC₅₀ values in the range of 1.2 to 3 μM. Soclenicant can be used in studies of anxiety, trauma, and stressor-related disorders .

HY-19490

VQW-765 AQW-051	nAChR	Neurological Disease
VQW-765 (AQW-051) is a selective and orally active alpha-7 nicotinic acetylcholine receptor (α7-nAChR) agonist with a pK_D value of 7.56 to recombinantly expressed human α7-nAChR. VQW-765 shows anxiolytic-like effect in vivo. VQW-765 can be used for the research of anxiety disorder and acute performance anxiety .

HY-12150

CCMI 1 Publications Verification AVL-3288; UCI-4083	nAChR	Neurological Disease
CCMI (AVL-3288) is a potent and selective α7 nAChR-positive allosteric modulator, does not bind to or activate α7 nAChRs via the orthosteric site, and causes significant positive modulation of agonist-induced currents at α7 nAChRs. CCMI has potential in CNS diseases with cognitive dysfunction .

HY-15430A

Encenicline hydrochloride 5 Publications Verification EVP-6124 hydrochloride	nAChR	Neurological Disease
Encenicline hydrochloride (EVP-6124 hydrochloride) is a novel partial agonist of α7 neuronal nicotinic acetylcholine receptors (nAChRs).

HY-146066

*α7 nAchR-JAK2-STAT3 agonist 1*	nAChR JAK STAT NO Synthase Interleukin Related	Inflammation/Immunology
α7 nAchR-JAK2-STAT3 agonist 1 is a potent α7 nAchR-JAK2-STAT3 agonist, with an IC₅₀ value of 0.32 μM for nitric oxide (NO). α7 nAchR-JAK2-STAT3 agonist 1 effectively suppresses the expression of iNOS, IL-1β, and IL-6 in murine RAW264.7 macrophages. α7 nAchR-JAK2-STAT3 agonist 1 can inhibit LPS-induced NO release, NF-κB activation and cytokine production. α7 nAchR-JAK2-STAT3 can be used for researching sepsis .

HY-12151

NS 1738 NSC 213859	nAChR	Neurological Disease
NS 1738 (NSC 213859) is a novel positive allosteric modulator of the α7 nAChR, with respect to positive modulation of α7 nAChR (EC₅₀=3.4 μM in oocyte experiments).

HY-105670

PHA-543613	nAChR	Neurological Disease
PHA-543613 is a potent, orally active, brain-penetrant and selective α7 nAChR agonist with a K_i of 8.8 nM. PHA-543613 displays selectivity for α7-nAChR over α3β4, α1β1γδ, α4β2 and 5-HT3 receptors . PHA-543613 can be used for the cognitive deficits of Alzheimer's disease and schizophrenia research .

HY-18060

Bradanicline TC-5619	nAChR	Neurological Disease
Bradanicline (TC-5619) is an orally active agonist of α7 nAChR with moderate blood-brain barrier penetration. Bradanicline exhibits high affinity and subtype selectivity for human α7 nAChR. Bradanicline possesses antitussive activity that depends on sustained receptor binding and activation. Bradanicline requires systemic administration to dose-dependently inhibit cough induced by citric acid, bradykinin and inhaled nicotine. Bradanicline is well tolerated in preclinical studies and is widely used in research related to chronic refractory cough .

HY-101955

(2S,6S)-Hydroxynorketamine hydrochloride (2S,6S)-HNK hydrochloride	mTOR nAChR	Neurological Disease
(2S,6S)-Hydroxynorketamine hydrochloride is a neurorelaxant with potential antidepressant and analgesic effects. (2S,6S)-Hydroxynorketamine hydrochloride can activate the mTOR pathway, increase the phosphorylation level of downstream targets, and antagonize α7-nicotinic acetylcholine receptor (nAChR) to exert neuroactive properties .

HY-12149

A-867744	nAChR	Neurological Disease
A-867744 is a highly potent and selective type II positive allosteric modulator (PAM) of the **alpha7 nicotinic acetylcholine receptors (nAChR) with an EC₅₀** of 1.0 μM .

HY-107682

TQS	nAChR	Neurological Disease Inflammation/Immunology
TQS is a α7 nicotinic acetylcholine receptor (nAChR) positive allosteric modulator. TQS can be used for the research of neuroinflammatory pain .

HY-110160

Pozanicline dihydrochloride ABT-089 dihydrochloride	nAChR	Neurological Disease
Pozanicline dihydrochloride (ABT-089 dihydrochloride) is an orally bioavailable nicotinic acetylcholine receptor (nAChR) agonist with a K_i of 16.7 nM for binding to [ ³H]cytisine sites . Pozanicline is an *α4β2*-selective *nAChR* agonist, which binds to rat brain α4β2 nAChR with a K_i of 17 nM while binding to α7 nAChR is insignificant .

HY-10019A

Varenicline dihydrochloride CP 526555 dihydrochloride	nAChR	Neurological Disease Inflammation/Immunology Cancer
Varenicline (CP 526555-18) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-114269

(-)-(S)-B-973B	nAChR	Neurological Disease Inflammation/Immunology
(-)-(S)-B-973B is an allosteric activator of α7 nicotinic acetylcholine receptor (α7 *nAChR*). (-)-(S)-B-973B alleviates pain behaviors. (-)-(S)-B-973B can be used for the research of inflammatory pain .

HY-N8249

Cynandione A	nAChR Interleukin Related	Inflammation/Immunology
Cynandione A is an acetophenone that can be isolated from Cynanchum Wilfordii Radix. Cynandione A protects hepatocytes and cortical neurons from toxicity and improves neurological deficits in a rat model of cerebral ischemia. On the other hand, cynandione A has significant anti-inflammatory effects and inhibits inflammation by activating macrophage α7 nAChR and IL-10 expression .

HY-19411

SSR180711 hydrochloride	nAChR	Neurological Disease
SSR180711 hydrochloride is an orally active, selective and reversible α7 acetylcholine nicotinic receptor (n-AChRs) partial agonist. SSR180711 hydrochloride can act on rat α7 n-AChR (K_i=22 nM; IC₅₀=30 nM) and human α7 n-AChR (K_i=14 nM; IC₅₀=18 nM). SSR180711 hydrochloride increases glutamatergic neurotransmission, ACh release and long-term potentiation (LTP) in the hippocampus .

HY-107672

MG624 Stilonium iodide	nAChR	Neurological Disease
MG624 is a potent and selective neuronal α7 nAChR antagonist with a K_i of 106 nM .

HY-161671

GAT2711	nAChR	Neurological Disease Inflammation/Immunology
GAT2711 is a full agonist of α9 nAChR with an EC₅₀ of 230 nM. GAT2711 shows 340-fold selective for α9 over α7 nAChRs. GAT2711 inhibits ATP-induced IL-1β release in THP-1 cells. GAT2711 retains full analgesic activity in α7 nAChR knockout mice .

HY-10063

Ispronicline TC-1734; ACD3480	nAChR	Neurological Disease
Ispronicline (TC-1734), an orally active, brain-selective *α4β2* nicotine acetylcholine receptor (nAChR) partial agonist, has shown memory-enhancing properties in rodents and a good tolerability profile. Ispronicline binds to the α4β2 nAChR with high affinity (K_i=11 nM) and is highly selective to other nAChRs such as α7 nAChR and α3β4 nAChR .

HY-108057A

Facinicline hydrochloride RG3487 hydrochloride	nAChR 5-HT Receptor	Neurological Disease
Facinicline hydrochloride (RG3487 hydrochloride) is an orally active nicotinic α7 receptor partial agonist, with a K_i of 6 nM for α7 human nAChR. Facinicline hydrochloride (RG3487 hydrochloride) improves cognition and sensorimotor gating in rodents. Facinicline hydrochloride (RG3487 hydrochloride) shows high affinity (antagonist) to 5-HT₃Rs with a K_i value of 1.2 nM .

HY-128575

BNC375	nAChR	Neurological Disease
BNC375 is a potent, selective, and orally available type I positive allosteric modulator of α7 nAChRs with an EC₅₀ of 1.9 μM. BNC375 exhibits good CNS-agent like properties and clinical candidate potential. .

HY-N0175R

Cytisinicline (Standard) Cytisine (Standard); Sophorine (Standard); Baptitoxine (Standard)	Reference Standards nAChR	Metabolic Disease Cancer
Cytisinicline (Standard) is the analytical standard of Cytisinicline. This product is intended for research and analytical applications. Cytisinicline (Cytisine) is an alkaloid. Cytisinicline (Cytisine) is a partial agonist of α4β2 nAChRs , and partial to full agonist at β4 containing receptors and α7 receptors . Has been used medically to help with smoking cessation .

HY-129674

PHA 568487 free base 1 Publications Verification	nAChR	Neurological Disease
PHA 568487 free base is a selective alpha 7 nicotinic acetylcholine receptor (α-7 *nAchR*) agonist. PHA 568487 free base reduces neuroinflammation .

HY-110087

4BP-TQS	nAChR	Neurological Disease
4BP-TQS is a potent allosteric agonist of α7 *nAChR. 4BP-TQS activates nAChRs* via an allosteric transmembrane site .

HY-15430

Encenicline EVP-6124	nAChR	Neurological Disease
Encenicline (EVP-6124) is a novel partial agonist of α7 neuronal nicotinic acetylcholine receptors (nAChRs).

HY-16748

Nelonicline ABT-126	nAChR	Neurological Disease
Nelonicline (ABT-126) is an orally active and selective α7 nicotinic receptor agonist with high affinity to α7 nAChRs in human brain (K_i=12.3 nM). Nelonicline is used for the research of shizophrenia and Alzheimer's disease .

HY-148325

α7 Nicotinic receptor agonist-1	nAChR	Neurological Disease
α7 Nicotinic receptor agonist-1 (Preparation 5) is an α7 nAChR agonist. α7 Nicotinic receptor agonist-1 can be used in studies of psychiatric disorders (such as schizophrenia, manic or hypomanic depression and anxiety disorders) and intellectual disorders (such as alzheimer's disease, learning deficits, cognitive deficits, attention deficits, memory loss, lewy body dementia and attention deficit hyperactivity disorder) .

HY-W698871

(±) Anabasine-d4	Isotope-Labeled Compounds Endogenous Metabolite	Others
(±) Anabasine-d4 is the deuterium labeled (±) Anabasine (HY-W052144). (±) Anabasine is the racemate of Anabasine (HY-B1532). Anabasine is an agonist of *α7nAChR* and exhibits anti-inflammatory and insecticidal activities .

HY-146066A

*(R)-α7 nAchR-JAK2-STAT3 agonist 1*	nAChR JAK STAT NO Synthase	Others
(R)-α7 nAchR-JAK2-STAT3 agonist 1 is the R-enantiomer of α7 nAchR-JAK2-STAT3 agonist 1 (HY-146066). α7 nAchR-JAK2-STAT3 agonist 1 is a potent α7 nAchR-JAK2-STAT3 agonist, with an IC₅₀ value of 0.32 μM for nitric oxide (NO). α7 nAchR-JAK2-STAT3 agonist 1 effectively suppresses the expression of iNOS, IL-1β, and IL-6 in murine RAW264.7 macrophages. α7 nAchR-JAK2-STAT3 agonist 1 can inhibit LPS-induced NO release, NF-κB activation and cytokine production. α7 nAchR-JAK2-STAT3 can be used for researching sepsis .

HY-133011

nAChR agonist 1	nAChR	Neurological Disease
nAChR agonist 1 is a potent, blood-brain-barrier-permeable, and orally active allosteric modulator of α7 nicotinic acetylcholine receptor (α7 nAChR). nAChR agonist 1 has the EC₅₀ of 0.32 μM in a Ca ²⁺ mobilization assay (PNU-282987-induced, FLIPR based) in human IMR-32 neuroblastoma cells that endogenously express α7 nAChR. nAChR agonist 1 can be develpoped for the treatment of Alzheimer’s disease .

HY-105670B

PHA-543613 dihydrochloride	nAChR	Neurological Disease
PHA-543613 dihydrochloride is a potent, orally active, brain-penetrant and selective α7 nAChR agonist with a K_i value of 8.8 nM. PHA-543613 dihydrochloride displays selectivity for α7-nAChR over α3β4, α1β1γδ, α4β2 and 5-HT3 receptors . PHA-543613 dihydrochloride can be used for the cognitive deficits of Alzheimer's disease and schizophrenia research .

HY-P5823

Azemiopsin	nAChR	Neurological Disease
Azemiopsin is a potent nicotinic acetylcholine receptor (nAChR) inhibitor with IC₅₀s of 0.18 μM and 22 μM against T. californica nAChR and human α7 nAChR, respectively. Azemiopsin blocks acetylcholine-induced currents in Xenopus oocytes heterologously expressing human muscle-type nAChR .

HY-14564

GTS-21	nAChR 5-HT Receptor	Inflammation/Immunology
GTS-21 dihydrochloride is a selective alpha7 nicotinic acetylcholine receptor *(α7-nAChR)* agonist with anti inflammatory and cognition enhancing activities. GTS-21 dihydrochloride is also a *α4β2* (K_i=20 nM for humanα4β2) and 5-HT3A receptor (IC₅₀=3.1 μM) antagonist. GTS-21 can be used in age-associated memory impairment (AAMI) and Alzheimer's disease research .

HY-12560D

PNU-282987 S enantiomer free base	nAChR	Others
PNU-282987 S enantiomer free base is the S-enantiomer of PNU-282987 free base. PNU-282987 is an α7 nicotinic acetylcholine receptor (α7 nAChR) agonist.

HY-11053

S 24795	nAChR	Neurological Disease
S 24795 is a partial agonist of α7 nAChR and improves mnemonic function in aged mice for the research of aging-related memory disturbances .

HY-107678

SEN12333 WAY-317538	nAChR	Neurological Disease
SEN 12333 (WAY-317538) is a potent, selective and orally active α7 nAChR agonist. SEN12333 displays high affinity for the rat α7 nAChRs expressed in GH4C1 cells (K_>i=260 nM) and acts as full agonist in functional Ca ²⁺ flux studies (EC₅₀=1.6 μM). SEN 12333 is used for AD and schizophrenia research .

HY-137231B

(S)-UFR2709 hydrochloride	nAChR	Neurological Disease
(S)-UFR2709 (hydrochloride) is a competitive *nAChR* antagonist?and displays higher affinity for α₄β₂ nAChRs than for α₇ nAChRs. (S)-UFR2709 (hydrochloride) decreases anxiety and reduces ethanol consumption and ethanol preference in alcohol-preferring rats. (S)-UFR2709 (hydrochloride) acts as an anxiolytic agent and can be used for the study of nicotine addiction .

HY-19490A

(S)-VQW-765 (S)-AQW-051	nAChR	Neurological Disease
(S)-VQW-765 ((S)-AQW-051) is an orally active, selective and effective α7 nicotinic ACh receptor (nAChR) partial agonist. (S)-VQW-765 has potential applications in cognitive disorders related to neurological diseases, such as Alzheimer's disease or schizophrenia .

HY-12560

PNU-282987 free base	nAChR 5-HT Receptor	Neurological Disease
PNU-282987 (free base) is a potent α7 nicotinic acetylcholine receptor (nAChR) agonist with an EC₅₀ of 154 nM. PNU-282987 (free base) is also a functional antagonist of the 5-HT₃ receptor with an IC₅₀ of 4541 nM. PNU-282987 (free base) can be used for the research of central and peripheral nervous systems .

HY-107666

PHA 568487	nAChR	Neurological Disease Inflammation/Immunology
PHA 568487 a selective agonist of alpha-7 nicotinic acetylcholine receptor (α-7 *nAchR*) .PHA 568487 reduces neuroinflammation and oxidative stress . PHA-568487 has rapid brain penetration .

HY-160529

*α7 nAChR* Modulator-2**	nAChR	Neurological Disease
α7 nAChR Modulator-2 (Compound 7b) is a α7 nAChR positive allosteric modulator (PAM) with an *EC₅₀ of 2.1 μM. α7 nAChR* Modulator-2 can be used for the research of cognitive disorders .**

HY-107683

LY-2087101	nAChR	Neurological Disease
LY-2087101 is an allosteric potentiator of α7 nAChRs. LY-2087101 causes potentiation of agonist-evoked α7 responses by binding within the nAChR transmembrane region .

HY-157958

*α7 nAChR* Modulator-3**	nAChR	Neurological Disease
α7 nAChR modulator-3 (Compound 6p) is a α7 nAChR positive allosteric Modulator with a IC₅₀ value of 1.3 μM. α7 nAChR Modulator-3 can be used to inhibit auditory gating defects in a mouse schizophrenic model .

Cat. No.	Product Name	Target	Research Area

HY-P1264

α-Bungarotoxin 5+ Cited Publications	nAChR	Neurological Disease
α-Bungarotoxin is a competitive antagonist at nicotinic acetylcholine receptors (nAChRs). α-Bungarotoxin, a selective α7 receptor blocker, blocks α7 currents with an IC₅₀ of 1.6 nM and has no effects on α3β4 currents at concentrations up to 3 μM .

HY-P5823

Azemiopsin	nAChR	Neurological Disease
Azemiopsin is a potent nicotinic acetylcholine receptor (nAChR) inhibitor with IC₅₀s of 0.18 μM and 22 μM against T. californica nAChR and human α7 nAChR, respectively. Azemiopsin blocks acetylcholine-induced currents in Xenopus oocytes heterologously expressing human muscle-type nAChR .

HY-P11470

Conofurin-Delta	nAChR SARS-CoV	Infection
Conofurin-Delta is a potent α7 nAChR inhibitor with an IC₅₀ of 177 nM. Conofurin-Delta also inhibits α9α10 nAChR with an IC₅₀ of 98.1 nM. Conofurin-Delta may be used in SARS-CoV-2 infection research .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-15310

Ivermectin Maximum Cited Publications 48 Publications Verification MK-933; CD-5024; K-237	Structural Classification Microorganisms Macrolide Antibiotics Classification of Application Fields Antibiotics Antiviral Anti-parasitic Disease Research Disease Research Fields Source Classification Cancer	Environmental Pollutants Antibiotic Mitophagy Bacterial Parasite Autophagy Flavivirus HSV HIV SARS-CoV Dengue Virus
Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin (MK-933) is a specific inhibitor of Impα/β1-mediated nuclear import and has potent antiviral activity towards both HIV-1 and dengue virus. It is a positive allosteric effector of P2X₄ and the α7 neuronal nicotinic acetylcholine receptor (nAChRs). Ivermectin also inhibits bovine herpesvirus1 (BoHV-1) replication and inhibits BoHV-1 DNA polymerase nuclear import . Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19 .

HY-N0175

Cytisinicline 1 Publications Verification Cytisine; Sophorine; Baptitoxine	Alkaloids Classification of Application Fields Leguminosae Pyridine Alkaloids Metabolic Disease Plants Thermopsis lanceolala R.Br. Disease Research Fields Source Classification	nAChR
Cytisinicline (Cytisine) is an alkaloid. Cytisinicline (Cytisine) is a partial agonist of α4β2 nAChRs , and partial to full agonist at β4 containing receptors and α7 receptors . Has been used medically to help with smoking cessation .

HY-W002112

(±)-Nornicotine Nornicotine	Structural Classification Alkaloids Pyrrole Alkaloids Neurological Disease Classification of Application Fields Pyridine Alkaloids Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite Drug Metabolite nAChR β-catenin
(±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial *nAChRs* agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia .

HY-N2255

Crebanine 4 Publications Verification	Cardiovascular Disease Structural Classification Alkaloids Stephania venosa Classification of Application Fields Other Alkaloids Plants Menispermaceae Inflammation/Immunology Disease Research Fields	Akt Apoptosis NF-κB Reactive Oxygen Species (ROS) p38 MAPK ERK Interleukin Related TNF Receptor NO Synthase nAChR Bacterial
Crebanine is an isoquinoline-like alkaloid that can be derived from Stephania. Crebanine is an antagonist of the *α7-nAChR* with an IC₅₀ of 19.1 μM. Crebanine suppresses the proliferation, migration, and invasion of cancer cells, triggers reactive oxygen species (ROS) burst, and promotes apoptosis. Crebanine inhibits the AKT/FoxO3a, NF-κB and MAPK signaling pathways. Crebanine attenuates NOX2 hyperactivation, exhibits antioxidant properties by reducing reactive oxygen species and peroxidation in microglia cells. Crebanine inhibits voltage-dependent Na ⁺ current in guinea-pig ventricular myocytes. Crebanine has high inhibitory activity against gram-positive animal pathogenic bacteria. Crebanine ameliorates ischemia-reperfusion brain damage in middle cerebral artery occlusion and reperfusion (MCAO/R) rats. Crebanine significantly improves Scopolamine (HY-N0296)-induced cognitive deficits in ICR mice. Crebanine can be used for the study of hepatocellular carcinoma (HCC), cerebral ischemia and Alzheimer's disease .

HY-N8249

Cynandione A	Apocynaceae Phenols Polyphenols Plants Cynanchum boudieri H. Lév. & Vaniot Source Classification	nAChR Interleukin Related
Cynandione A is an acetophenone that can be isolated from Cynanchum Wilfordii Radix. Cynandione A protects hepatocytes and cortical neurons from toxicity and improves neurological deficits in a rat model of cerebral ischemia. On the other hand, cynandione A has significant anti-inflammatory effects and inhibits inflammation by activating macrophage α7 nAChR and IL-10 expression .

HY-N0175R

Cytisinicline (Standard) Cytisine (Standard); Sophorine (Standard); Baptitoxine (Standard)	Alkaloids Structural Classification Leguminosae Pyridine Alkaloids Plants Thermopsis lanceolala R.Br. Source Classification	Reference Standards nAChR
Cytisinicline (Standard) is the analytical standard of Cytisinicline. This product is intended for research and analytical applications. Cytisinicline (Cytisine) is an alkaloid. Cytisinicline (Cytisine) is a partial agonist of α4β2 nAChRs , and partial to full agonist at β4 containing receptors and α7 receptors . Has been used medically to help with smoking cessation .

HY-114791

Lobelanidine	Alkaloids Lobelia tupa L. Other Alkaloids Campanulaceae Plants Source Classification	nAChR
Lobelanidine is an antagonist for nicotinic acetylcholine receptor (nAChR), which inhibits α7 nAChR response and α3β2/α3β4 nAChR responses, with IC₅₀ of 2.8 and 8.2 μM .

HY-W052144

(±) Anabasine 2 Publications Verification	Alkaloids Piperidine Alkaloids Other disease Classification of Application Fields Disease markers Other Diseases Pyridine Alkaloids Endogenous metabolite Disease Research Fields Source Classification	Endogenous Metabolite
(±) Anabasine is the racemate of Anabasine (HY-B1532). Anabasine is an agonist of *α7nAChR* and exhibits anti-inflammatory and insecticidal activities .

HY-W052144R

(±) Anabasine (Standard)	Alkaloids Piperidine Alkaloids Structural Classification Other disease Disease markers Pyridine Alkaloids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite
(±) Anabasine is the racemate of Anabasine (HY-B1532). Anabasine is an agonist of α7nAChR and exhibits anti-inflammatory and insecticidal activities .

HY-W002112R

(±)-Nornicotine (Standard) Nornicotine (Standard)	Structural Classification Alkaloids Pyrrole Alkaloids Pyridine Alkaloids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Drug Metabolite nAChR β-catenin
(±)-Nornicotine (Standard) is the analytical standard of (±)-Nornicotine (HY-W002112). This product is intended for research and analytical applications. (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial *nAChRs* agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia .

HY-N18367

Lemairamin Wgx-50	Zanthoxylum bungeanum Maxim. Structural Classification Simple Phenylpropanols Rutaceae Phenylpropanoids Plants Source Classification	nAChR Interleukin Related Akt
Lemairamin (Wgx-50) is a hydroxylamine compound. Lemairamin can be isolated from the pericarps of the Zanthoxylum plants. Lemairamin activates *α7nAChR, stimulates the expression of IL-10* and POMC. Lemairamin shows a decrease in Akt. Lemairamin attenuates DSS-induced intestinal inflammation. Lemairamin alleviates pain hypersensitivity .

HY-N2332

Methyllycaconitine MLA	Structural Classification Alkaloids Piperidine Alkaloids Ranunculaceae Delphinium ajacis Plants Source Classification	nAChR
Methyllycaconitine (MLA) is a potent, selective, CNS-penetrant, competitive *α7nAChR* antagonist. Methyllycaconitine alleviates amyloid-β peptides-induced cytotoxicity in SH-SY5Y cells. Methyllycaconitine prevents methamphetamine-induced effects in mouse striatum. Methyllycaconitine can be used for neurological disease research, such as Alzheimer’s disease .

Cat. No.	Product Name	Chemical Structure

HY-W698871

(±) Anabasine-d4
(±) Anabasine-d4 is the deuterium labeled (±) Anabasine (HY-W052144). (±) Anabasine is the racemate of Anabasine (HY-B1532). Anabasine is an agonist of *α7nAChR* and exhibits anti-inflammatory and insecticidal activities .

HY-W002112S

(±)-Nornicotine-d4

(±)-Nornicotine-d₄ is the deuterium labeled (±)-Nornicotine (HY-W002112). (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia .

HY-106901AS

Asoxime-d4 dichloride

1 Publications Verification

Asoxime-d₄ dichloride (HI-6-d₄) is the deuterium labeled Asoxime dichloride. Asoxime dichloride is an orally active thiosemicarbazone-based antidote. Asoxime dichloride is a reversible inhibitor of AChE, and its core mechanism of action is to re-activate AChE inhibited by nerve toxins, thereby restoring the cholinergic nerve function. Asoxime dichloride significantly restores the function of poisoned muscles without reactivating AChE. Asoxime dichloride is an antagonist of acetylcholine receptors (AChRs), including nicotinic receptor and α7 nAChR. Asoxime dichloride can serve as an effective immunomodulator, improving the immune effect of the nervous system.

HY-115766S

Anabaseine-d4
Anabaseine-d₄ is the deuterium labeled Anabaseine (HY-115766). Anabaseine is a non-selective nicotinic agonist. Anabaseine stimulates all AChRs, preferentially stimulates skeletal muscle and brain α7 subtypes . Anabaseine is also a weak partial agonist at α4β2 nAChRs .

HY-W052144S

(±) Anabasine-d4 dihydrochloride
(±) Anabasine-d₄ dihydrochloride is deuterium labeled (±) Anabasine dihydrochloride. (±) Anabasine dihydrochloride is the racemate of Anabasine dihydrochloride. Anabasine dihydrochloride is an agonist of *α7nAChR* and exhibits anti-inflammatory and insecticidal activities .

HY-10019S2

Varenicline-13C15N

Varenicline- ¹³C ¹⁵N (CP 526555- ¹³C ¹⁵N) is ¹³C and ¹⁵N labeled Varenicline. Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀ = 250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-10019S1

Varenicline-15N,13C,d2

Varenicline- ¹⁵N, ¹³C,d₂ is ¹⁵N and deuterated labeled Varenicline (HY-10019). Varenicline (CP 526555) is an orally active partial agonist of α4β2 nicotinic acetylcholine receptor (α4β2 nAChR, IC₅₀=250 nM), which is the principal mediator of nicotine dependence. Varenicline is also a partial agonist of α6β2 nAChR and a full agonist of α7β2 nAChR. Varenicline blocks the direct agonist effects of nicotine on nAChR while stimulates nAChR in a more moderate way, being widely used as an aid of smoking cessation .

HY-10019S

Varenicline-d4

Varenicline-d₄ is deuterium labeled Varenicline. Varenicline (CP 526555) is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC₅₀ value of 2.3 μM. Varenicline is a full agonist for α3β4 and α7 nAChRs with EC₅₀ values of 55 μM and 18 μM, respectively . Varenicline is a nicotinic ligand based on the structure of cytisine, has the potential for smoking cessation treatment .

HY-10019AS1

Varenicline-d4 hydrochloride

Varenicline-d₄ hydrochloride is a deuterium labeled Varenicline (dihydrochloride) (HY-10019A) . Varenicline (CP 526555) dihydrochloride is a potent partial agonist for α4β2 nicotinic acetylcholine receptor (nAChR) with an EC₅₀ value of 2.3 μM. Varenicline dihydrochloride is a full agonist for α3β4 and α7 nAChRs with EC₅₀ values of 55 μM and 18 μM, respectively . Varenicline dihydrochloride is a nicotinic ligand based on the structure of cytosine, and has the potential for smoking cessation treatment .

HY-B0072S

Tropisetron-d5

Tropisetron-d₅ (SDZ-ICS-930-d₅ (free base)) is deuterium labeled Tropisetron. Tropisetron (SDZ-ICS-930 free base) is an orally active anti-inflammatory and antiemetic agent. Tropisetron is 5-HT₃R antagonists with a K_i of 5.3 nM. Tropisetron is also a partial agonist of α7 nicotinic receptor (α7 nAChR) with an EC₅₀ of 1.3 μM. In addition, Tropisetron has antitumor and neuroprotective effects .

HY-W743727

Cytisine-d4
Cytisine-d₄ is the deuterium labeled Cytisinicline (HY-N0175). Cytisinicline (Cytisine) is an alkaloid. Cytisinicline (Cytisine) is a partial agonist of α4β2 nAChRs , and partial to full agonist at β4 containing receptors and α7 receptors . Has been used medically to help with smoking cessation .

HY-W002112S1

(±)-Nornicotine-d7

(±)-Nornicotine-d₇ is the deuterium labeled (±)-Nornicotine (HY-W002112). (±)-Nornicotine is a major metabolite of Nicotine. (±)-Nornicotine is a partial nAChRs agonist, specifically activating receptor subtypes containing α7 and α6 subunits. (±)-Nornicotine disrupts β-catenin and ZO-1, and induces F-actin depolymerization. (±)-Nornicotine supports self-administration behavior. (±)-Nornicotine can be used in the research of atherosclerosis, Alzheimer's disease, and schizophrenia .

Cat. No.	Compare	Product Name	Application	Reactivity	Image

HY-P83668

	CHRNA7 Antibody (YA3499) 7nAChR,CHRFAM7A,CHRNA7 (cholinergic receptor; nicotinic; alpha 7; exons 5-10) and FAM7A (family with sequence similarity 7A; exons A-E) fusion; D-10; CHRNA7; CHRNA7-DR1	IHC-P, FC, ELISA	Human
	CHRNA7 Antibody (YA3499) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to CHRNA7.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Cat. No.	Product Name		Classification

HY-14318

Altinicline SIB-1508Y free base		Alkynes
Altinicline (SIB-1508Y free base) is a selective *α4β2* nicotinic acetylcholine receptor (nAChR) agonist, with no activity against α7 or *α1β1γδ* nAChRs and only extremely low activity against *α3β4* nAChRs. Altinicline reverses escape deficits and increases avoidance responses. Altinicline is applicable to research related to depression .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks